Loading...

DENALI CAPITAL ACQUISITION CORP Management Changes 8-K Filing

DNL

DENALI CAPITAL ACQUISITION CORP

()

2026 8-K

Leadership Changes

Securities Update

Merger Announcement

Merger Agreement Approved

Investment Agreement

Merger of Equals

Asset Acquisitions

Shareholder Meeting

Delisting Notice

Business Combination Extension

Business Extension

Business Combination Extension

Deadline Extension

Deadline Extension

Deadline Extension

Nasdaq Compliance Notice

Deadline Extension

Merger Agreement

Convertible Promissory Note...

Dismissal and Appointment o...

Convertible Promissory Note...

Business Combination Announ...

Termination of Merger Agree...

Shareholder Meeting

Postponement of Shareholder...

Amended and Restated Subscr...

Convertible Promissory Note...

Investor Presentation

Merger Agreement and Conver...

Merger Agreement

External Links:

On March 13, 2026, Semnur Pharmaceuticals announced the retirement of CEO Jaisim Shah and appointed Henry Ji as the new CEO, while Stephen Ma will become the Chief Operating Officer on March 17, 2026. Shah will receive a severance package totaling $625,000 for six months after his effective departure date.

AI Assistant

DENALI CAPITAL ACQUISITION CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.